东方生物：“炎症标志物检测试剂盒”等产品取得注册证

Core Insights - The core viewpoint of the article highlights the significant revenue contribution of the in vitro diagnostics sector to Dongfang Biological's overall business, indicating a strong focus on this industry segment [1]. Company Overview - Dongfang Biological's revenue composition for the year 2024 is reported as 97.99% from the in vitro diagnostics industry and 2.01% from other business activities [1]. - The company announced on August 4 that it has obtained several medical device registration certificates through its subsidiaries, including the "Inflammatory Marker Test Kit" and has recently achieved overseas medical device registration for a respiratory panel test [3]. Industry Context - The in vitro diagnostics industry is a critical area for Dongfang Biological, as evidenced by its overwhelming revenue share, suggesting a robust market presence and potential for growth in this sector [1].